NASDAQ:BLCM Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.07▼$0.0950-Day Range$0.07▼$0.1052-Week Range$0.06▼$1.31Volume6,059 shsAverage Volume22,874 shsMarket Capitalization$726,570.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsOwnershipTrendsStock AnalysisEarningsOwnershipTrends Get Bellicum Pharmaceuticals alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Read More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here BLCM Stock News HeadlinesFebruary 22, 2024 | msn.comBellicum sells assets to MD Anderson, moves towards liquidationJanuary 25, 2024 | msn.comBellicum Pharmaceuticals Issues Super-Voting Share PrivatelyJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.December 23, 2023 | morningstar.comBellicum Pharmaceuticals Inc BLCMDecember 8, 2023 | benzinga.comBellicum Pharmaceuticals Stock (OTC:BLCM), Short Interest ReportOctober 27, 2023 | finance.yahoo.comFutura Medical plc (FAMDF)July 13, 2023 | finance.yahoo.comBLCM - Bellicum Pharmaceuticals, Inc.June 3, 2023 | fool.comBellicum Pharmaceuticals (NASDAQ: BLCM)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 8, 2023 | investorplace.comWhy Is Bellicum Pharmaceuticals (BLCM) Stock Up 75% Today?April 18, 2023 | msn.comWhy Digital Brands Group Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving PremarketApril 18, 2023 | benzinga.comShort Volatility Alert: Bellicum PharmaMarch 15, 2023 | msn.comBLCM Plummets on Stopping Trials of BPX-601 and BPX-603March 15, 2023 | msn.comWhy Bellicum Pharmaceuticals (BLCM) Stock Is Down 48%March 14, 2023 | finance.yahoo.comBellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic AlternativesFebruary 24, 2023 | finance.yahoo.comWhy Bellicum Pharmaceuticals Stock Is Plunging TodayFebruary 16, 2023 | finance.yahoo.comBellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers SymposiumJanuary 31, 2023 | finance.yahoo.comCORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive BLCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BLCM CUSIPN/A CIK1358403 Webwww.bellicum.com Phone(281) 454-3424FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,970,000.00 Net MarginsN/A Pretax Margin-1,492.40% Return on EquityN/A Return on Assets-157.93% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio3.04 Sales & Book Value Annual Sales$1.50 million Price / Sales0.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book0.33Miscellaneous Outstanding Shares9,720,000Free Float8,716,000Market Cap$726,570.00 OptionableNot Optionable Beta1.39 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David M. Maggio (Age 64)Chief Executive Officer Mr. Joseph Senesac (Age 54)Senior Vice President of Technical Operations & Quality Dr. Alan K. Smith Ph.D. (Age 66)Chief Scientific Officer Comp: $536.43kKey CompetitorsPolarityTENASDAQ:PTEIQ9 Meters BiopharmaNASDAQ:NMTRKaleido BiosciencesNASDAQ:KLDO180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWView All Competitors BLCM Stock Analysis - Frequently Asked Questions How were Bellicum Pharmaceuticals' earnings last quarter? Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its earnings results on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company had revenue of $0.70 million for the quarter. When did Bellicum Pharmaceuticals' stock split? Bellicum Pharmaceuticals's stock reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Bellicum Pharmaceuticals IPO? Bellicum Pharmaceuticals (BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager. What other stocks do shareholders of Bellicum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX) and Gilead Sciences (GILD). This page (NASDAQ:BLCM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellicum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellicum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.